Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Editas Medicine Inc
EDIT | US
3.76
USD0.40
11.90%
EDIT | US
About Editas Medicine Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
3.76
Open
3.35
High
3.80
Low
3.28
Editas Medicine Inc. a clinical stage genome editing company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101 which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301 a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover develop and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine Inc. was incorporated in 2013 and is based in Cambridge Massachusetts.
View LessEDIT | US
Risk
72.2
Sharpe
-0.67
Luna's Score
45/100
Recommendation
Sell
Luna says (EDIT | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
85.0%1 month
72.2%3 months
67.4%6 months
69.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.18
Debt to equity
0.17
Debt to assets
0.10
Ent. to EBITDA
-1.36
Ent. to rev.
0.49
PEG
-
Other Fundamentals
EBITDA
-207.21M
MarketCap
310.11M
MarketCap(USD)
310.11M
Div. yield
-
Op. margin
-14.02K
Erngs. growth
-
Rev. growth
-82.20
Ret. on equity
-61.23
Short ratio
8.23
Short perc.
25.72
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.89
Range1M
0.89
Range3M
2.94
Volumes: Market Activity
Rel. volume
2.33
Price X volume
17.23M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.36 | - | Cheaper |
| Ent. to Revenue | 0.49 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.18 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 67.41 | - | Par |
| Debt to Equity | 0.17 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 310.11M | - | Emerging |
